{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:05:32Z","timestamp":1756339532164,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,3,20]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>A 57-year-old man with a history of diabetes and coronary artery disease was referred to haematology for the evaluation of anaemia in the setting of non-cardiac chest pain, fatigue, dyspnoea and dizziness. Previous investigations into these recurrent symptoms focused on a re-evaluation of his known ischaemic heart disease, which required multiple percutaneous interventions with stenting several years ago. In the year leading up to his referral, the patient required two transfusions during separate hospitalisations. Previously, his chronic anaemia was attributed to chronic inflammation because of unrevealing micronutrient and endoscopic evaluations. The patient underwent a bone marrow biopsy, which demonstrated normal karyotype myelodysplastic syndrome with ringed sideroblasts. This patient was found to have favourable cytogenetics and low-risk disease. His anaemia and associated symptoms improved with the administration of an erythroid-stimulating agent. Now 75 years old, he has remained on single-agent therapy for 10 years without need of transfusion.<\/jats:p>","DOI":"10.1136\/bcr-2019-232285","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T05:50:45Z","timestamp":1586238645000},"page":"e232285","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Low-risk myelodysplastic syndrome managed with an erythroid-stimulating agent for 10 years"],"prefix":"10.1136","volume":"13","author":[{"given":"Anthony","family":"Esparza","sequence":"first","affiliation":[{"name":"Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-9872","authenticated-orcid":false,"given":"Raj Chandra","family":"Singaraju","sequence":"additional","affiliation":[{"name":"Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"},{"name":"Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Paul","family":"Happel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"2025082708464242000_13.4.e232285.1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.15707","article-title":"Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review","volume":"184","author":"Park","year":"2019","journal-title":"Br J Haematol"},{"key":"2025082708464242000_13.4.e232285.2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"2025082708464242000_13.4.e232285.3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) . Myelodysplastic syndromes, 2019."},{"key":"2025082708464242000_13.4.e232285.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"2025082708464242000_13.4.e232285.5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajh.25397","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \"2019 Update on Diagnosis, Risk-stratification, and Management\"","volume":"94","author":"Patnaik","year":"2019","journal-title":"Am J Hematol"},{"key":"2025082708464242000_13.4.e232285.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-342642"},{"key":"2025082708464242000_13.4.e232285.7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00063-002-1210-4","article-title":"[Myelodysplastic syndromes. Diagnosis and therapeutic strategies]","volume":"97","author":"Aul","year":"2002","journal-title":"Med Klin"},{"key":"2025082708464242000_13.4.e232285.8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2014.04.010","article-title":"Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants","volume":"15","author":"Xie","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082708464242000_13.4.e232285.9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1515\/jtim-2017-0002","article-title":"The 2016 revision to the world Health organization classification of myelodysplastic syndromes","volume":"5","author":"Hong","year":"2017","journal-title":"J Transl Int Med"},{"key":"2025082708464242000_13.4.e232285.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211797"},{"key":"2025082708464242000_13.4.e232285.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.11.037"},{"key":"2025082708464242000_13.4.e232285.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157279","article-title":"Erythropoietin levels in elderly patients with anemia of unknown etiology","volume":"11","author":"Gowanlock","year":"2016","journal-title":"PLoS One"},{"key":"2025082708464242000_13.4.e232285.13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007559"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:46:51Z","timestamp":1756309611000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,6]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bcr-2019-232285"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232285","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}